Partners: Apple Victory Will Not Hurt Samsung Smartphone Sales

Printer-friendly version Email this CRN article

A federal jury's decision Thursday to award Apple $290 million in a patent dispute with rival Samsung is not going to slow Samsung's sales momentum in the smartphone market, according to solution providers.

"This is a non-issue for customers," said Ira Grossman, CTO of end user and mobile computing for MCPc, a nationwide technology integrator specializing in mobile solutions with its Anyplace Workspace. "Customers want companies to innovate. This is just noise that gets in the way. We have never had a customer say they are apprehensive about buying a Samsung device because of pending patent litigation. It just doesn't happen."

The verdict covers older Samsung devices that another jury had found infringed Apple patents.

[Related: The Great Tablet Race: IDCs Top 5 Tablet Brands]

Another trial is scheduled for next year to consider claims on newer Samsung devices.

Grossman said the patent infringement issues are "beyond the level of what businesses and consumers can comprehend and understand especially on older devices when those features and functions are no longer relevant."

The verdict comes with Samsung maintaining its big lead in the smartphone market with 31.4 percent of the market share over Apple's 13.1 percent, according to IDC's third-quarter report.

The $290 million the jury award amounts to a drop in the bucket for the $180 billion company, said Grossman.

Michael Oh, the founder and CEO of Tech Superpowers, an Apple-focused IT solution provider with offices in Boston and London, said he does not expect the jury award to impact sales but counted it as a reaffirmation of Apple's innovation superiority in the overall mobile market.

"Is [Apple] going to sell more iPads or Macs tomorrow?" he asked rhetorically. "Doubtful. What it does do is raise the pedestal that Apple is on as an innovator by a couple of inches."

NEXT: Partners React On The Innovation Question

Printer-friendly version Email this CRN article